The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessAbstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 3,101–3,200 of 4,628
Zhao, Q., Mo, N., Li, R., Wei, T. T., Xu, W., Wang, J., Li, S., Zhu, H., & Miao, G. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03804-9 · Cited by 3
Wang, W., Chen, S., Xi, Z., Si, Y., Liu, Y., Chen, J., Wang, B., Zhu, D., & Gong, L. (2025) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0527oc · Cited by 4
Halder, D., Khan, M. S., Sue, T., Ali, M., Jahan, U. M. S., Atiquzzaman, M., Khatun, M., Islam, M. K., Keya, R. B., Hasan, A., et al. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110867 · Cited by 3
Fan, L., Shetty, R. S., Dao, H. M., Balnadupete, A., Somasundram, B., Bhagavath, A. K., Kongara, A., Tang, H., Citrin, D. E., Williams, R. O., et al. (2025) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00295.2024 · Cited by 3
Fang, Y., Hsieh, Y.-A., Chen, Y., et al. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03890-9 · Cited by 3
Idiopathic fibrotic lung disease at a university hospital setting: management and prognostic factors
Rad, P., Karlsson, C.-A., & Janson, C. (2015) · European Clinical Respiratory Journal · doi:10.3402/ecrj.v2.26915 · Cited by 3
Not yet known side effects of pirfenidone in the treatment of idiopathic pulmonary fibrosis?
Campainha, S., Nogueira, C., Costa, F. C., et al. (2015) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppnen.2015.10.002 · Cited by 3
Gastroesophageal Reflux in Idiopathic Pulmonary Fibrosis: More than a Gut Feeling?
Wuyts, W. A., & Collard, H. R. (2016) · Respiration · doi:10.1159/000443183 · Cited by 3
Self-citationSpagnolo, P., Sverzellati, N., & Rossi, G. (2016) · Respirology · doi:10.1111/resp.12824 · Cited by 3
Cordeiro, C. R., Alfaro, T. M., Freitas, S., & Cemlyn-Jones, J. M. (2015) · European Respiratory Society eBooks · doi:10.1183/2312508x.10009414 · Cited by 3
Recent advances in managing systemic sclerosis
Aringer, M., & Erler, A. (2017) · F1000Research · doi:10.12688/f1000research.10022.1 · Cited by 3
Idiopathic pulmonary fibrosis: time for greater expectations?
Wuyts, W. A., & Cottin, V. (2018) · European Respiratory Journal · doi:10.1183/13993003.01312-2018 · Cited by 3
Self-citationPericytes and T Cells in Lung Injury and Fibroproliferation
Birbrair, A., Prazeres, P. H. D. M., Files, D. C., & Delbono, O. (2018) · Molecular and translational medicine · doi:10.1007/978-3-319-98143-7_7 · Cited by 4
Comprehensive Care in Pulmonary Fibrosis
Molina‐Molina, M., & Wijsenbeek, M. S. (2018) · Barcelona Respiratory Network · doi:10.23866/brnrev:2018-0021 · Cited by 3
Wolters, P. J., & Cottin, V. (2019) · European Respiratory Journal · doi:10.1183/13993003.00283-2019 · Cited by 3
Self-citationIdiopathic pulmonary fibrosis: accurate diagnosis and early treatment
Morais, A. (2019) · Jornal Brasileiro de Pneumologia · doi:10.1590/1806-3713/e20190353 · Cited by 3
“In 2014, the results of two clinical trials of two different medications, pirfenidone(7) and nintedanib,(8) demonstrated a positive impact on the evolution of IPF by significantly reducing the decline in pulmonary function as measured by FVC, compared with a placebo, over the period of 52 weeks.”
BackgroundResultFLT1: a potential therapeutic target in sepsis-associated ARDS?
Hall, I. P. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30404-7 · Cited by 3
Update in Imaging of Idiopathic Pulmonary Fibrosis
Kaproth-Joslin, K. A., Croake, M. F., & Hobbs, S. (2020) · Advances in Clinical Radiology · doi:10.1016/j.yacr.2020.04.004 · Cited by 3
Sgalla, G., Mari, P., & Richeldi, L. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3243 · Cited by 3
Self-citationProgressive fibrosing interstitial lung disease: we know it behaves badly, but what does that mean?
Wongkarnjana, A., & Ryerson, C. J. (2020) · European Respiratory Journal · doi:10.1183/13993003.00894-2020 · Cited by 3
Management of idiopathic pulmonary fibrosis: A survey of Canadian respirologists
Fidler, L. M., Burns, K. E. A., Singer, L. G., Kiss, A., Shapera, S., & Stanbrook, M. B. (2020) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2020.1767524 · Cited by 3
Guellec, S. L., Allimonnier, L., Heuzé‐Vourc'h, N., Cabrera, M., Ossant, F., Pourchez, J., Vecellio, L., & Plantier, L. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.01022 · Cited by 4
Investigation of telomere related gene mutations in idiopathic pulmonary fibrosis
Yıldırım, H., Yildiz, P., & Coşkunpınar, E. M. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05861-1 · Cited by 4
Yamazaki, R., Nishiyama, O., Yoshikawa, K., Saeki, S., Sano, H., Iwanaga, T., & Tohda, Y. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245778 · Cited by 3
“The diagnosis of IPF was based on the eligibility criteria adopted in the INPULSIS trial [12].”
MethodPharmacological Interventions for Pulmonary Involvement in Rheumatic Diseases
Kang, E. H., & Song, Y. W. (2021) · Pharmaceuticals · doi:10.3390/ph14030251 · Cited by 5
Karayama, M., Aoshima, Y., Yasui, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-87452-z · Cited by 3
Deep Learning Approach for Auto-Detecting Idiopathic Pulmonary Fibrosis Prediction
Wang, Z. (2021) · IEEE International Conference on Artificial Intelligence and Industrial Design (AIID) · doi:10.1109/aiid51893.2021.9456590 · Cited by 3
Resistance Training for Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis
Vainshelboim, B., & MYERS, J. N. (2021) · Translational Medicine and Exercise Prescription · doi:10.53941/tmep.v1i1.34 · Cited by 2
Special considerations for pulmonary rehabilitation in conditions other than COPD
Cavalheri, V., Vainshelboim, B., Evans, R. A., da Fontoura, F. F., & Lee, A. L. (2021) · European Respiratory Society eBooks · doi:10.1183/2312508x.10018220 · Cited by 3
Beyond TGFβ1 - novel treatment strategies targeting lung fibrosis
Sim, C., Lamanna, E., Cirnigliaro, F., & Lam, M. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106090 · Cited by 3
Villeneuve, T., Prévôt, G., Lintz, F., Mourin, G., Ferry, G., Bousquet, E., Perelroizen, H., Boghanim, T., Faviez, G., Noël-Savina, É., et al. (2021) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2021.07.004 · Cited by 3
Antifibrotic therapies for idiopathic pulmonary fibrosis
Akbar, I., Mann, J., Niewodowski, D., Mackintosh, J. A., Glaspole, I., & Barnes, H. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015076 · Cited by 3
Manzetti, G. M., Hosein, K., Cecchini, M. J., Kwan, K. F., Abdelrazek, M., Zompatori, M., Rogliani, P., & Mura, M. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01753-7 · Cited by 3
Tseng, C.-M., Chen, M.-Y., Kao, C.-Y., & Tao, C.-W. (2022) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000719 · Cited by 5
Fibrose pulmonaire idiopathique : actualisation des recommandations pratiques
Cottin, V., Bonniaud, P., Cadranel, J. L., Jouneau, S., Marchand-Adam, S., Nunès, H., Wémeau-Stervinou, L., & Crestani, B. (2022) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.03.004 · Cited by 4
Self-citationHong, M.-J., Hao, M., Zhang, G., et al. (2022) · Marine Drugs · doi:10.3390/md20070448 · Cited by 3
Is Carob Flour Helpful in Reducing Diarrhoea Associated With Nintedanib?
Alsina‐Restoy, X., Torres‐Castro, R., Caballeria, E., Sisó-Comabella, M., Romano‐Andrioni, B., Pérez-Rodas, N., Noboa-Sevilla, M. B., Francesqui, J., Hernández‐González, F., & Sellarés, J. (2023) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2022.12.014 · Cited by 3
Taweesedt, P. T., Lertjitbanjong, P., Eksombatchai, D., Charoenpong, P., Moua, T., Thongprayoon, C., Tangpanithandee, S., & Petnak, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020655 · Cited by 5
Mondoni, M., Varone, F., Alfano, F., et al. (2023) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2023.02.010 · Cited by 3
Self-citationHealth Care Disparities in Pulmonary Fibrosis—Time to Move the Needle Forward
Mageto, Y. N. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.2442 · Cited by 3
Nakashima, T., Omori, K., Namba, M., Yamaguchi, K., Sakamoto, S., Horimasu, Y., Masuda, T., Miyamoto, S., Iwamoto, H., Fujitaka, K., et al. (2023) · Respiratory Medicine · doi:10.1016/j.rmed.2023.107224 · Cited by 4
Matsumura, T., Makino, T., Yagisawa, M., Ishige, M., Akimoto, Y., Ito, K. R., Anami, Y., & Kono, M. (2023) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2023.101846 · Cited by 3
Pulmonary Alveolar Proteinosis Syndrome
O’Callaghan, M., McCarthy, C., & Trapnell, B. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-12950-6_22 · Cited by 3
Lybéris, P., Verri, G., Solidoro, P., Femia, F., PEROTTI, C., Limerutti, G., Delsedime, L., Beffa, E. D., Papotti, M. G., Ruffini, E., et al. (2023) · Minerva Surgery · doi:10.23736/s2724-5691.23.09948-3 · Cited by 3
Kim, K.-I., Hossain, R., Li, X., Lee, H. J., & Lee, H. J. (2023) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2023.056 · Cited by 3
Mendoza, F. A., Allawh, T., & Jiménez, S. A. (2022) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/am4nmv · Cited by 5
Clinical significance of high monocyte counts for the continuous treatment with nintedanib
Tsuneyoshi, S., Zaizen, Y., Tominaga, M., Matama, G., Umemoto, S., Ohno, S., Takaki, R., Yano, R., Murotani, K., Okamoto, M., et al. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02536-y · Cited by 4
Hollmén, M., Bromilow, T., Smith, A. B., Mealing, S., Lewis, D., Galvin, L., Jones, S., Pacheco, L., Soulard, S., & Froidure, A. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s408857 · Cited by 3
Hollmén, M., Wijsenbeek, M. S., Bromilow, T., Smith, A. B., Mealing, S., Lewis, D., Galvin, L., Jones, S., Asijee, G. M., Soulard, S., et al. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s409767 · Cited by 3
Fang, H., Dong, T., Han, Z., Li, S., Liu, M., Liu, Y., Yang, Q., Fu, M., & Zhang, H. (2023) · International Journal of COPD · doi:10.2147/copd.s426763 · Cited by 6
Mandovra, N. P., Vaidya, P. J., Shah, R., Nighojkar, A., Chavhan, V. B., Lohiya, A., Leuppi, J. D., Taegtmeyer, A. B., & Chhajed, P. N. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206513 · Cited by 4
Nintedanib-associated enterocolitis with intractable diarrhea: a case report
Miyaguchi, K., Tsuzuki, Y., Uemuara, H., Ishizawa, K., Shinomiya, S., Matsumoto, H., Shiomi, R., Ohgo, H., Nagata, M., Nakamoto, H., et al. (2023) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-023-01894-8 · Cited by 3
Jang, J. H., Ko, J., Jung, S. Y., Kim, D.-W., Oh, J. H., Kim, T. J., Park, J. H., Choi, M., & Lee, J. H. (2023) · Life · doi:10.3390/life13122318 · Cited by 4
Self-citationComplications of fibrotic interstitial lung disease for the general radiologist
Watson, S., Dixon, G., Savill, A., Gibbons, M., Barratt, S. L., & Rodrigues, J. C. L. (2024) · Clinical Radiology · doi:10.1016/j.crad.2024.01.015 · Cited by 4
Imai, M., Okabayashi, H., Akaike, K., Hamada, S., Masunaga, A., Ichiyasu, H., & Sakagami, T. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.01.013 · Cited by 3
Ash, S. Y., Doyle, T. J., Choi, B., Estépar, R. S. J., Castro, V., Enzer, N. A., Kalhan, R., Liu, G. Y., Bowler, R. P., Wilson, D. O., et al. (2024) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2023-002219 · Cited by 3
Gunsalus, P. R., Rose, J., Lehr, C. J., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0296839 · Cited by 3
Serum netrin-1 levels are high in Rheumatoid arthritis associated interstitial lung disease
Kor, A., Güven, S. C., Akan, S., Eren, F. K., Konak, H. E., Maraş, Y., Orhan, K., Neşelioğlu, S., & Erten, Ş. (2024) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2024.110760 · Cited by 4
A modular simulation framework for organ allocation
Rose, J., Gunsalus, P. R., Lehr, C. J., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.04.063 · Cited by 3
“7,11,12 21 To date, the primary simulation tools used have been the Simulated Allocation Models (SAMs) developed by the Scientific Registry of Transplant Recipients (SRTR): the LSAM (liver), 22 KPSAM (kidney/pancreas), 23 and the TSAM (thorax).”
Postoperative pulmonary function of patients with lung cancer and interstitial lung abnormalities
Tsubokawa, N., Mimae, T., Mimura, T., Kagimoto, A., Kamigaichi, A., Kawamoto, N., Miyata, Y., & Okada, M. (2024) · General Thoracic and Cardiovascular Surgery · doi:10.1007/s11748-024-02037-7 · Cited by 3
Cuesta, V. M. M., Meñaca, A. M., González-Fernández, Á., Fernandez, D. I., Tello-Mena, S., Izquierdo‐Cuervo, S., Fernández-Rozas, S., Alonso‐Lecue, P., & Martínez, J. M. C. (2024) · Heart & Lung · doi:10.1016/j.hrtlng.2024.04.022 · Cited by 3
Deng, J., Liu, J., Chen, W., Liang, Q., He, Y.-Q., & Sun, G. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s388920 · Cited by 6
Ma, L., Liu, C., Zhao, Y., Liu, M., Liu, Y., Zhang, H., Yang, S., An, J., Tian, Y., Cao, Y., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1374669 · Cited by 3
Adewale, A. T., Sharma, S., Mouawad, J. E., Nguyen, X.-X., Bradshaw, A. D., & Feghali‐Bostwick, C. A. (2024) · Matrix Biology · doi:10.1016/j.matbio.2024.06.002 · Cited by 3
Interstitial lung disease in systemic lupus erythematosus: State of the art search
Santacruz, J. C., Mantilla, M. J., Rodríguez-Salas, G., et al. (2024) · Revista Colombiana de Reumatología (English Edition) · doi:10.1016/j.rcreue.2022.10.006 · Cited by 3
Kang, M., Gupta, S., Tu, Y.-H., Raimundo, K., Patel, A. M., & Flaherty, K. R. (2024) · CHEST Pulmonary · doi:10.1016/j.chpulm.2024.100082 · Cited by 3
Self-citationEnomoto, N., Nakai, S., Yazawa, S., Mochizuka, Y., Fukada, A., Tanaka, Y., Naoi, H., Inoue, Y., Yasui, H., Karayama, M., et al. (2024) · Respiratory Research · doi:10.1186/s12931-024-02982-0 · Cited by 4
Self-citationRautajoki, T., Rantala, H. A., Sutinen, E., Saarto, T. H., Rajala, K., Pesonen, I., Hollmén, M., Myllärniemi, M., & Lehto, J. T. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03303-3 · Cited by 7
Erol, A. Y. G., Dirol, H., & Koçancı, F. G. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70018 · Cited by 2
Investigational gene expression inhibitors for the treatment of idiopathic pulmonary fibrosis
Spagnolo, P., Tonelli, R., Mura, M., Reisman, W. M., Sotiropoulou, V., & Tzouvelekis, A. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2462592 · Cited by 3
Wan, Y., Li, W., Zhu, H., Ai, S., & Lin, W. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00183h · Cited by 3
Cough in idiopathic pulmonary fibrosis: what is new
da Silva, M. A. C., Rolo, R., Catarata, M. J., et al. (2025) · Breathe · doi:10.1183/20734735.0176-2024 · Cited by 3
Cheema, S., Saddique, M. N., Jha, A., et al. (2025) · Heart & Lung · doi:10.1016/j.hrtlng.2025.05.008 · Cited by 3
de Lima, F. R., Viana, J. D. O., Castro, A., et al. (2025) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70152 · Cited by 3
Lin, F., Lin, K., Li, D., Kong, W., Zhuang, J., He, W., Wei, X., Xiao, T., Zu, H., Zhang, Z., et al. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03696-9 · Cited by 3
Todd, J. L., Neely, M. L., Hellkamp, A. S., Culver, D. A., Oldham, J. M., Li, P., Patel, D. C., Palmer, S. M., & on behalf of the IPF-PRO Registry investigators (2025) · Lung · doi:10.1007/s00408-025-00845-z · Cited by 6
Andrisano, A. G., Castaldo, N., Giuliana, F., Femia, D., Morana, G., Patruno, V., Monteleone, G., Reccardini, N., Cifaldi, R., Hughes, M., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186665 · Cited by 8
“To date, nintedanib, an oral tyrosine kinase inhibitor, is an antifibrotic drug that has been approved for the treatment of IPF and progressive pulmonary fibrosis (PPF) [8,9].”
InfluentialNeumonías intersticiales idiopáticas
Tenes, A., Gómez-Carrera, L., García‐Sánchez, A., et al. (2018) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2018.11.002 · Cited by 3
Palladium-Catalyzed One-Pot Approach to 3-(1,3-Diarylprop-2-yn-1-ylidene)oxindoles
Seo, J. H., Park, S., Shin, K. J., et al. (2018) · Heterocycles · doi:10.3987/com-18-13975 · Cited by 3
Kalnins, P., Brucker, M., & Spears, D. (2018) · The Permanente Journal · doi:10.7812/tpp/18-074 · Cited by 3
Advances in CT Diagnosis of UIP and IPF
Thiessen, R., Fenwick, J. L., & Lynch, D. A. (2018) · Seminars in Roentgenology · doi:10.1053/j.ro.2018.12.001 · Cited by 5
Nintedanib in Severe Idiopathic Pulmonary Fibrosis: Effectiveness through Compassion
Tzouvelekis, A., & Bouros, D. E. (2018) · Respiration · doi:10.1159/000488647 · Cited by 4
Chronic Lung Pathologies That Require Repair and Regeneration
de Hilster, R. H. J., Li, M., Timens, W., Hylkema, M. N., & Burgess, J. K. (2019) · Springer eBooks · doi:10.1007/978-3-030-29403-8_1 · Cited by 3
Choi, W.-I. (2021) · Precision and Future Medicine · doi:10.23838/pfm.2020.00205 · Cited by 3
“In patients with IPF, the FVC of the group treated with nintedanib for 52 weeks decreased less by approximately 100 mL compared to the placebo group [34].”
BackgroundMethodInfluentialHumoral Immune Status in Relation to Outcomes in Patients with Idiopathic Pulmonary Fibrosis
Hoffman, T. W., van Moorsel, C. H. M., Kazemier, K. M., Biesma, D. H., Grutters, J. C., & van Kessel, D. A. (2021) · Lung · doi:10.1007/s00408-021-00488-w · Cited by 4
The Syndrome of Combined Pulmonary Fibrosis and Emphysema
Cottin, V., & Cordier, J.-F. (2014) · Springer eBooks · doi:10.1007/978-1-4471-2401-6_22 · Cited by 4
Self-citationA Small Molecule That Promotes Cellular Senescence Prevents Fibrogenesis and Tumorigenesis
Meang, M. K., Kim, S., Kim, I. H., Kim, H.-S., & Youn, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126852 · Cited by 4
Road Toward a New Model of Care for Idiopathic Pulmonary Fibrosis in the Lazio Region
Bidino, R. D., Rogliani, P., Sebastiani, A., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.861076 · Cited by 3
Self-citationLuo, M., & Wang, J. (2022) · Respirology Case Reports · doi:10.1002/rcr2.1032 · Cited by 2
“Moreover, the side effect profile of antifibrotic treatment in patients with TRG mutation is similar to those observed in the general IPF population.(3,6) In our case, steroids temporarily relieved the symptoms for a few months, but dyspnea continued to worsen afterward, and antifibrotics failed to slow the progressio…”
ResultAvdeev, S. N., Ilkovich, M. M., Terpigorev, S. A., Moiseev, S. V., & Tyurin, I. E. (2023) · Life · doi:10.3390/life13020483 · Cited by 5
“At the same time, in patients not receiving antifibrotic therapy, the decrease in FVC within 6 months should be at least 110 mL [24,25].”
BackgroundOn Bedrosian Condition In Application To Chirp Sounds
Hermanowicz, E. (2007) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.40452 · Cited by 3
Jenkins, G. R. (2014) · Thorax · doi:10.1136/thoraxjnl-2014-206209 · Cited by 3
Personalizing Therapy in Idiopathic Pulmonary Fibrosis: A Glimpse of the Future?
Kropski, J. A., Lawson, W. E., & Blackwell, T. S. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201509-1789ed · Cited by 3
Panorama actual de la fibrosis pulmonar idiopática en México
Barreto-Rodríguez, J. O., Mejía, M. E., & Buendía-Roldán, I. (2015) · NCT Neumología y Cirugía de Tórax · doi:10.35366/63377 · Cited by 3
Targeted treatment of idiopathic pulmonary fibrosis: one step at a time
Richeldi, L. (2016) · European Respiratory Journal · doi:10.1183/13993003.00389-2016 · Cited by 3
Self-citationLung Function Testing in Idiopathic Pulmonary Fibrosis: More Than Just Spirometry?
Clara, P. C., González, C. M., & Ancochea, J. (2016) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2016.07.009 · Cited by 3
Galectin-3: Distant Biomarker or Relevant Target?
Keane, M. P. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201601-0192ed · Cited by 3
How we will diagnose IPF in the future
Richeldi, L. (2016) · QJM · doi:10.1093/qjmed/hcw116 · Cited by 3
Self-citationIPF in 2016: towards a better diagnosis
Spagnolo, P., Sverzellati, N., & Rossi, G. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30375-7 · Cited by 3
Immunopathogenesis and Immune-based Therapy for Selected Autoimmune Disorders
Aribi, M. (2017) · InTech eBooks · doi:10.5772/63032 · Cited by 3
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.